Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724769 | 0.82 | TSHR (0.35) | TSHR | |
| SCHEMBL22325533 | 0.80 | TSHR (0.52) | TSHR | |
| SCHEMBL7787116 | 0.80 | TSHR (0.33) | TSHR | |
| SCHEMBL530220 | 0.80 | TSHR (0.33) | TSHR | |
| SCHEMBL21530765 | 0.79 | TSHR (0.30) | TSHR | |
| SCHEMBL530525 | 0.78 | LMNA (0.41) | TSHR | |
| SCHEMBL244781 | 0.78 | TSHR (0.32) | TSHR | |
| SCHEMBL6269584 | 0.78 | TSHR (0.32) | TSHR | |
| SCHEMBL4334239 | 0.76 | MGAM (0.35) | TSHR | |
| SCHEMBL6724775 | 0.76 | TSHR (0.31) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396354-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024130217-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130218-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4370503-A1 | ESTERS OF A RETINOID AND BAKUCHIOL AND PREPARATIONS THEREOF | Conagen Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024097746-A1 | ALKENE CYCLOPROPANATION WITH NICKEL CATALYST ENHANCER AND IMPROVED REARRANGEMENT REACTION | CONAGEN INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4355350-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-4340859-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | Biohaven Therapeutics Ltd. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4337639-A1 | NAMPT INHIBITORS AND USES THEREOF | Remedy Plan, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024050554-A2 | SYNTHESIS OF COTYLENIN AND ANALOGS THEREOF FOR THE DEVELOPMENT OF SELECTIVE MODULATORS OF 14-3-3 PROTEIN-PROTEIN INTERACTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024020188-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | AMYLYX PHARMACEUTICALS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2014130612-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-8586020-B2 | Poly(organophosphazene) composition for biomaterials | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| EP-2231633-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-10-30 | — | — | EP | disclosed |
| EP-2598522-A2 | RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015691-A2 | RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-2183229-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009017671-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008080986-A1 | FURAN DERIVATIVES, METHOD OF SYNTHESIS AND USES THEREOF | NEUROPHARMA, S.A. (ES) | 2008-07-10 | — | — | WO | disclosed |
| EP-1684754-A1 | HMG-COA REDUCTASE INHIBITORS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005051386-A1 | HMG-COA REDUCTASE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |